cMET-directed CAR-T cells

cMET-directed CAR-T cells are a form of autologous cell therapy in which a patient's own T lymphocytes are genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets the MET proto-oncogene (also known as hepatocyte growth factor receptor or HGFR). The extracellular domain of the CAR is typically derived from an antibody fragment that recognizes the c-MET protein on tumor cell surfaces. Upon binding to c-MET-expressing cancer cells, these modified T-cells become activated and mediate cytotoxicity against the tumor through cytokine release and direct killing. This approach is being investigated for several solid tumors where overexpression of c-MET is implicated in disease progression and poor prognosis—including hepatocellular carcinoma (HCC), colorectal cancer (COAD), non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), mesothelioma, and breast cancer. Some versions use mRNA electroporation for transient expression; others use viral vectors for stable integration[1][4][5].

Other names

c-Met-targeted chimeric antigen receptor T cellsMET-CAR-Tanti-c-Met CAR-T